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Background: [18 F]AFM is a potent and promising PET imaging agent for the serotonin transporter. We carried out
an acute toxicity study in rats and radiation dosimetry in monkeys before the translation of the tracer to humans.
Methods: Single- and multiple-dose toxicity studies were conducted in Sprague–Dawley rats. Male and female rats
were injected intravenously with AFM tartrate as a single dose of 98.7 or 987 μg/kg (592 or 5,920 μg/m2, 100× or
1,000× the proposed human dose of 8 μg, respectively) on day 1 or as five consecutive daily doses of 98.7 μg/kg/day
(592 μg /m2/day, 100× human dose, total dose 493.5 μg/kg). PET/CT scans were performed in four Formosan rock
monkeys (two males and two females, each monkey scanned twice) using a Siemens BIOGRAPH scanner. After
injection of [18 F]AFM (88.5 ± 20.3 MBq), a low-dose CT scan and a series of eight whole-body PET scans in 3-D
mode were performed. Time-activity data of source organs were used to calculate the residence times and
estimate the absorbed radiation dose using the OLINDA/EXM software.
Results: In the rats, neither the single dose nor the five daily doses of AFM tartrate produced overt adverse effects
clinically. In the monkeys, the radiation doses received by most organs ranged between 8.3 and 39.1 μGy/MBq. The
osteogenic cells, red marrow, and lungs received the highest doses of 39.1, 35.4, and 35.1 μGy/MBq, respectively. The
effective doses extrapolated to male and female adult humans were 18.0 and 18.3 μSv/MBq, respectively.
Conclusions: Toxicity studies in Sprague–Dawley rats and radiation dosimetry studies in Formosa rock monkeys
suggest that [18 F]AFM is safe for use in human PET imaging studies.
Trial registration: IACUC-12-200.
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Abnormalities in the serotonin transporter (SERT) have
been implicated in several neurologic and psychiatric
disorders [1,2]. SERT is also the target for selective sero-
tonin reuptake inhibitors (SSRIs), a class of compounds
used as antidepressants clinically [3,4]. Thus, in vivo SERT
imaging in humans would assist in the early diagnosis as
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in any medium, provided the original work is pdiseases [5]. The isoquinoline analog [11C]-(+)McN5652
was the first PET agent for studying SERT in humans
[6-8]. However, this agent has high nonspecific binding and
has only moderate signal contrast in human PET studies
[9]. In addition, 18 F has some advantages over 11C, notably
that the 18 F-labeled radioligands can be transported off-site
due to its longer half-life. Thus, two of its fluorine-18-
labeled analogs, S-[18 F]fluoroethyl)-(+)-McN5652 [10] and
S-[18 F]fluoromethyl)-(+)-McN5652 [11], have been synthe-
sized and evaluated as SERT imaging agents. The S-[18 F]
fluoromethyl)-(+)-McN5652, in particular, has recently
been shown to be suitable for in vivo quantification of
SERT with PET in human [12]. In addition to isoquinoline,
the diaryl sulfides N,N-dimethyl-2-(arylthio)benzylaminesn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ity and affinity for SERT binding sites [13].Thus, [11C]3-
amino-4-(2-dimethylaminomethyl-phenylsulfanyl)benzoni-
trile ([11C]DASB) [14], [11C]2-[2-(dimethylaminomethyl)
phenylthio] -5-fluoromethylphenylamine ([11C]AFM)
[15], [11C] N,N-dimethyl-2-(2-amino-4-methylphenyl-
thio)benzylamine ([11C]MADAM) [16], and [11C]N,N-
dimethyl-2-(2′-amino-4′-hydroxymethyl -phenylthio)
benzylamine ([11C]HOMADAM) [17] were also syn-
thesized and found to be the potential radioligands for
studying SERT in humans [18-21]. The results of these
studies showed that all of these carbon-11-labeled
diphenyl sulfides were better than [11C]-(+)-McN5652
as SERT imaging agents for human studies. Thus, some of
their 18 F-labeled analogs, such as 2-[(2-amino-4-chloro-5-
[18 F]fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine
([18 F]-ACF) [22], N,N-dimethyl-2-(2-amino-4-[18 F]fluoro-
phenylthio)benzylamine (4-[18 F]-ADAM) [23-25], N,N-di-
methyl-2-(2-amino-5-[18 F]fluorophenylthio)-benzylamine
(5-[18 F]-ADAM) [26], 2-[[2-amino-4-([18 F]fluoromethyl)
phenyl]thio]-N,N-dimethylbenzenemethanamine ([18 F]
AFM) [27], 2-(2′-((dimethylamino)methyl)-4′-(3-[18 F]
fluoropropoxy)phenylthio)benzenamine ([18 F]FPBM) [28],
and 3-amino-4-(2-((4-[18 F]fluorobenzyl)methylamino)
methylphenylsulfanyl)-benzonitrile ([18 F]FBASB) [29]
have been synthesized and evaluated in animals as poten-
tial SERT imaging agents [22,26-33]. Of these 18 F-labeled
diaryl sulfides, 4-[18 F]-ADAM and [18 F]AFM have been
shown to possess proper characteristics as brain SERT im-
aging agents for human studies [24,34]. Thus, we have
studied the toxicity and radiation dosimetry of 4-[18 F]-
ADAM in rats and monkeys. The results showed that 4-
[18 F]-ADAM was safe and suitable for human studies
[35], and the results of the distribution of 4-[18 F]-ADAM
in human brain were reported recently [36]. In order to
access the suitability of [18 F]AFM as a brain SERT im-
aging agent for human studies, we report herein the tox-
icity and radiation dosimetry of [18 F]AFM in rats and
monkeys before its human studies are undertaken.
Methods
The protocols used for this study were similar to those
used for the study of 4-[18 F]-ADAM [35].
Synthesis of AFM tartrate
The AFM tartrate was synthesized according to the
method reported previously [27]. The identity and
chemical purity of this compound were confirmed by
1H NMR, mass spectroscopy, HPLC analysis, and elemen-
tal analysis.
Toxicity studies
The toxicity studies were performed in male and female
Sprague–Dawley rats by the Biosciences Division of theSRI International (SRI), Menlo Park, CA and were fully
supported by the NIMH Toxicological Evaluation of
Novel Ligands Program.
Animal procedures conducted at SRI were approved
by SRI’s Institutional Animal Care and Use Committee
(IACUC). SRI’s animal facilities have been accredited
by the Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC)
and are registered with the US Department of Agriculture
as a Research Facility. SRI files assurances with the Public
Health Service (PHS) Office of Laboratory Animal
Welfare (OLAW) and adheres to PHS standards and
practices.
Animals
Forty male (6 to 6 1/2 weeks old, weighing 143 to 250 g)
and 40 female (7 to 7 1/2 weeks old, weighing 152 to
213 g) Sprague–Dawley rats (Charles River Laboratories,
Wilmington, MA, USA) were used in this study. Upon
arrival, the rats were placed in quarantine for 3 days.
The general appearance of the animals was evaluated by
the attending veterinarian, who documented that the
animals were healthy before releasing them from quar-
antine. The rats were fed with Purina Certified Rodent
Chow, #5002 (Purina Mills, Richmond, IN, USA) ad
libitum. Water (purified, reverse osmosis) was provided
ad libitum during quarantine and study periods. The
rats were housed (five per cage) in clear polycarbonate
cages in an animal room that was monitored for
temperature (70°F to 74°F) and humidity (29% to 58%) in
a light cycle of 12 h light/12 h dark.
Preparation of dose formulation
The test article, AFM tartrate, was formulated in sterile
phosphate buffered saline (PBS) (AMRESCO, Inc., Solon,
OH, USA). Dose formulations were prepared by dissolving
the appropriate amount of test article in the vehicle to
achieve target concentrations using a sterile stir bar and
sonication. Lower concentrations were achieved by serial
dilution from the high dose concentration. Doses were
based on the free base (290.49 g/mol; 65.95% of total mo-
lecular weight). Dose formulations were stored frozen up
to 7 days at −72°C to −76°C until the day of use. Formula-
tions were brought to room temperature prior to adminis-
tration to the animals. Drugs were administered through
intravenous (iv) injection via lateral tail vein. The intraven-
ous route is intended for human clinical trials. Therefore,
iv injection was selected to model the intended route of
human administration.
Verification of formulation
All AFM tartrate formulations used for the toxicity studies
were analyzed by SRI staff using reversed-phase HPLC
methods [Luna C18 analytical column (4.6 × 250 mm,
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water; solvent B: 0.1% TFA in CH3CN; gradient: solvent
A/solvent B 85/15 for 10 min, 50/50 for 1 min, 85/15 for
4 min; flow rate: 1.0 mL/min; UV detector: 240 nm;
ambient temperature]. The HPLC system used was
Hewlett-Packard Model 1100 Series liquid chromatog-
raphy system (Agilent Technologies, Inc., Santa Clara,
CA, USA). Data were analyzed using HP Chemstation
Software, version A. 06.04. Concentration, homogeneity,
and stability of the formulation were confirmed before
testing and were found to be within 10% of the target con-
centrations for all treatment groups.
Dosage calculation
The procedures used to determine the AFM tartrate
dose to be administered to rats required that all doses
were converted from units of mg/kg (body weight) to
units of body surface area expressed in mg/m2. Basing
the dose on body surface allows for determination of
an equivalent dose to another species. The equation
used was:
Dose mg kg
   F ¼ Dose mg m2= Þð

where F is a constant based on the species of animal
being tested (a value of 37 for humans) [37]. Doses were
based on the body weight recorded on day 1 before
dosing (and converted to mg/m2 surface area), and pre-
set multiples of the maximum proposed 8-μg dose to be
administered to a 50-kg person were administered to the




No. of animals 10 10
Dose per day By surface area (μg/m2) 0 5,920
By body weight (μg/kg) 0 987
No. dosages 1 1
Total dosage (μg/kg) 0 987
Dosage volume (mL/kg) 7.58 7.58
Rats killedb
Interim Day 3 3
No. of killed 5 5
Terminal Day 15 15
No. of killed 5 5
aMaximum human dose is 8 μg per 50-kg person, i.e., 0.16 μg/kg; 0.16 × 37 = 5.92 μ
human dosage. 1,000 × 0.987 = 987 μg/kg as the high dosage; bFive rats in each gro
five on day 15 (14 days following single dosing). Five rats in each group and of eac
(14 days following 5-day dosing). Dosing of the 5-day dosing animals was initiated
on the same calendar day for all groups, thus allowing sharing of control clinical paexpressed in both mg/kg and mg/m2, as well as individual
species F values can be found in Table 1.
Dosing procedure
Male and female rats (10/sex/gp) were given a single iv
dose of AFM tartrate at 98.7 or 987 μg/kg (592 or
5,920 μg/m2, 100× or 1,000× the proposed human dose
of 8 μg, respectively) on day 1 or daily iv dose on days
1 to 5 for five consecutive days at 98.7 μg/kg/day
(592 μg/m2/day, 100× human dose, total dose of
493.5 μg/kg). A control group (10/sex) was given a single
iv dose of vehicle, 1% ascorbic acid in sterile phosphate
buffered saline, at an equivalent volume on day 1. Dose in-
jection of the repeat dose group was initiated 4 days prior
to dosing of the single dose animals so that necropsies
occur on the same calendar day for all groups, thus allow-
ing for sharing of control clinical pathology and necropsy
data between the two dose regimens.
Observation protocol
All animals in this study were observed at least once
daily for signs of mortality, morbidity, injury, and avail-
ability of food and water. Detailed clinical observations
were recorded daily throughout the study. Individual
body weights were measured and recorded for each ani-
mal on day 1 prior to dosing and at necropsy (days 3
and 15 for groups 1 to 3 and days 7 and 19 for group 4).
Food consumption was measured for an approximately
24-h period twice weekly throughout the study. Blood
for clinical pathology evaluation was collected on days 3
and 15 (interim and terminal necropsy of groups 1 to 3)








10 10 10 10
592 0 5,920 592
98.7 0 987 98.7
1/5 1 1 1/5
98.7/493.5 0 987 98.7/493.5
7.58/7.58 7.58 7.58 7.58/7.58
3/7 3 3 3/7
5/5 5 5 5/5
15/19 15 15 15/19
5/5 5 5 5/5
g/m2. Scaling for the rat gives 5.92 μg/m2/6 = 0.987 μg/kg as an equivalent
up and of each sex were killed on day 3 (2 days following single dosing) and
h sex were killed on day 7 (2 days following 5-day dosing) and five on day 19
4 days prior to dosing of the single-dose animals so that necropsies occurred
thology and necropsy data between the two dosage regimens.
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pentobarbital (150 mg/kg) administered by intraperitoneal
injection.
Clinical pathology
After collection at SRI, the clinical pathology samples were
sent to Quality Clinical Labs, Inc (Mountain View, CA,
USA). Blood samples were collected into tubes containing
ethylenediaminetetraacetic acid (EDTA) (hematology
samples), sodium citrate (coagulation samples), or no
anticoagulant (serum chemistry samples).
Gross necropsy
On days 3 and 15 (interim and terminal necropsy of
groups 1 to 3) or days 7 and 19 (interim and terminal
necropsy of group 4), after recording of body weight and
collection of clinical pathology blood samples, animals
were sacrificed and given a complete postmortem examin-
ation, which included a thorough inspection of all body
orifices and surfaces and an examination of all cranial,
thoracic, and abdominal organs. Organ weights were mea-
sured for adrenal glands, brain, heart, kidneys, liver,
spleen, thymus, testes, and ovaries. All of the organs and
tissues were retained and fixed in phosphate buffered 10%
formalin.
Histopathologic examination
Sections of the retained tissues were embedded in paraf-
fin, cut approximately 5-μm thick, and stained with
hematoxylin and eosin by Environmental Pathology
Laboratories, Inc. (Sterling, VA, USA). All tissues from
the animals in the control and treated groups were
examined by a board-certified veterinary pathologist. If a
tissue had gross findings at the time of necropsy, the same
tissue from the other dosage groups was also examined.
Statistical analyses
One-way ANOVA was performed for body weight, food
consumption, organ weights, and clinical pathology data
(LABCAT® modules: In-Life v. 6.2, HE v.4.42, and OW v.
3.24). When appropriate, a post hoc analysis (Dunnett’s
t-test) was carried out. In all cases, the lower limit for
statistical significance was defined as p ≦ 0.05.
Dosimetry studies of [18 F]AFM in monkeys
Synthesis of [18 F]AFM
The radioligand [18 F]AFM (2) was synthesized by the
reported method (Scheme 1) [27] except using an au-
tomated synthesizer as previously described for the
synthesis of 4-[18 F]-ADAM [25]. Briefly, nucleophilic
fluorination of 2-[2-(dimethylaminomethyl)phenylthio]-5-
chloromethylphenylamine (1) (6.6 mg in 0.1 mL of DMSO
and 0.4 mL of t-BuOH) with dried potassium [18 F]fluor-
ide/Kryptofix2.2.2 at 85°C for 15 min followed by reductionwith Cu(OAc)2 (21 mg in 1 mL of EtOH) and NaBH4
(8.2 mg in 0.6 mL of EtOH) at 80°C for 20 min and
purification with HPLC (EP250/16 Nucleosil 100–7 C18
column, 16 × 250 mm, 10 μm, Macherey-Nagel, MN,
USA); Mobile phase: CH3CN:0.1 M HCO2NH4 (30:70
containing 0.3 vol.% acetic acid); flow rate: 10 mL/min.
The HPLC product fraction was diluted with excess of
H2O (250 mL) and passed through a tC18 cartridge into
the waste bottle. The tC18 cartridge was rinsed with an
additional 10 mL of H2O into the waste bottle. The [
18 F]
AFM retained in tC18 cartridge was rinsed out with 1 mL
of EtOH into a vial which contained 10 mL of normal
saline and was then passed through a Millipore filter
(Cathivex GS, 0.22 mm; Millipore, Billerica, MA, USA)
into a sterile vial. The formulated solution contains less
than 10% EtOH in normal saline. The radiochemical
yield of [18 F]AFM was 0.6% ± 0.1% (EOS) (n = 8) in a
synthesis time of 100 min from EOB. The radiochemical
purity of the product was greater than 98% with a spe-
cific activity of 62.9 ± 18.5 GBq/μmol (1.7 ± 0.5 Ci/μmol)
(n = 8). TLC (Silica gel/CH3OH:CH2Cl2 (1:9), Rf = 0.55)
and HPLC (C18 column: Phenomonex Luna (2), 5 μm,
4.6 × 250 mm; mobile phase: CH3CN:0.1 M HCO2NH4
(30:70 with 0.3 vol.% acetic acid)); flow rate: 1 mL/min;
Rt = 10.5 min showed that [18 F]AFM was not contami-
nated with [18 F]fluoride and was stable for more than
4 h in the formulated solution.
Animals
The animal study protocol used for this study was approved
by the IACUC of the National Defense Medical College.
Four Formosan rock monkeys (Macaca cyclopis), two
females, 2.70 and 2.85 kg, respectively, and two males,
5.78 and 7.25 kg, respectively, were used in the dosimetry
study. Animals were fasted overnight and immobilized
with ketamine (2 mg/kg), anesthetized with 2% isoflurane
via an endotracheal tube, and administered with atropine
sulfate (2 mg i.m.) to minimize secretions during the
course of the experiment. Body temperature was kept
constant at 37°C with a heated blanket. The heart rates
pO2 and pCO2 were checked every 10 min and kept in the
normal range throughout the imaging sessions.
PET imaging protocol
Whole-body transmission and emission scans were
acquired with a Biograph PET/CT scanner (Biograph
Duo, Siemens, Knoxville, TN, USA), which has 58.5-cm
transverse field-of-view (FOV), 15.5-cm axial FOV, and
4.8-mm FWHM spatial resolution. After [18 F]AFM
(88.5 ± 20.3 MBq, 2.4 ± 0.5 mCi; n = 8) injection, a low
dose CT scan (130 kVp, 50 mAs) and a series of eight
whole-body PET scans were performed (15, 55, 95, 110,
155, 170, 215, and 230 min, respectively, post-injection).
Total acquisition time was 240 min. Each scan covered
Scheme 1 Synthesis of [18 F]AFM (2). (a) K[18 F]/K2.2.2, DMSO/t-BuOH, 85°C; (b) NaBH4-Cu(OAc)2, EtOH, 80°C.
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sisted of five or six bed positions depending on the size
of the monkey. In each bed position, data were acquired
for 2 min in 3-D mode. The data were then recon-
structed by Ordered-Subsets Expectation-Maximization
(OSEM) on a 128 × 128 matrix (slice thickness, 5 mm),
with two iterations and eight subsets, 3-mm FWHM
gaussian filter, and corrected by photon attenuation
using the CT scan.
Image analysis
For all organs except bone, the image analysis and resi-
dence time calculations were performed by the reported
methods with some modifications [35,38]. Each CT and
PET whole-body images of [18 F]AFM were successively
loaded to the PMOD 2.5 software (PMOD technologies,
Zurich, Switzerland; www.pmod.com) to generate the fu-
sion images, and the organs were identified and outlined.
Regions of interest (ROIs) of these organs were manually
drawn as precisely as possible on the organ itself on each
horizontal slice. The bone uptake of [18 F]AFM was de-
termined by the bone ROI that was drawn in the fore-
arm over the radii and ulnae (left and right) on the
transmission scan and then applied to the correspond-
ing PET image. Because the bone marrow is primarily
located in the ribs, vertebrae, and pelvis but not in the
distal limbs [39], the uptake of [18 F]AFM in the bone
marrow was derived from ROIs of the lumbar vertebrae.
The activity in each organ was non-decay-corrected and
expressed as percent-injected dose per organ (n = 8,
mean ± SD).
Residence times and absorbed dose calculations
To calculate the radiation dose of each organ as well as
the effective dose, the injected dose of [18 F]AFM and
the non-decay-corrected time-activity curves (TACs) of
the brain, lungs, heart, liver, spleen, kidneys, radii, ulnae,
lumbar vertebrae, and bladder of the four monkeys were
individually entered into an Excel spreadsheet and thedata processed individually for each animal. The differ-
ence between the injected dose and the sum of the
whole-body radioactivity (assuming that there was no
excretion) plus the radioactivity in the above-mentioned
organs was taken as the TAC of the remainder.
The residence time (h) of the selected organ was cal-
culated as the area under the TAC of the source organ
from time 0 to infinity over the initial total body activity
(about 5 half-lives of 18 F, i.e., about 550 min). The area
under the TAC of each organ was generated using the
following strategy including trapezoidal integration of
the first four TAC data points through the origin and ex-
ponential decline of the four remaining TAC data points
to infinity such that the residence times of these organs
were obtained [40].
The residence time (h) of bone and the bone marrow
were estimated using the reported method [38]. Briefly,
since the bone mass of the ulna and radius equals 4.3%
of all bone mass in the body [41], the residence time of
all bones in the body was calculated as that of the radii
and ulnae divided by 4.3%.
The residence time of all red marrow in the body was
estimated from the lumbar vertebrae, which contains
both red marrow and bone. Since the mass of the red
marrow in lumbar vertebrae equals 12.3% of the mass of
all red marrow in the body [42], the residence time of
the red marrow in the body was calculated as that of all
radioactivity in the lumbar vertebrae minus that from
the bone component and then divided by 12.3%.
The human dosimetry was estimated from both male
and female monkey biodistribution data. Except for the
bone and red marrow, the organ weight and body mass
were used for allometric scaling [43]. That is, the residence
time in each organ was converted to the corresponding hu-
man value by multiplication with a factor to scale organ
and body weights (in kilograms) as (wm,b/wm,o)(wh,o/wh,b),
where wm,b was the monkey body weight, wm,o was the
monkey organ weight, wh,b was the human body weight,
and wh,o was the human organ weight. However, the wm,o
Figure 1 Typical sagittal view of [18 F]AFM whole-body images of a male Formosan rock monkey at different time points.
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instead, we used the wm,o values for the rhesus monkey
(Macaca mulatta) in our calculations. Both monkey organ
weights [44] and human organ weights [45] were obtained
from the literatures. Monkey bone and red marrow wereTable 2 Biodistribution and residence times of [18 F]AFM in Fo
%ID/organ
Brain Lungs Heart Liver S
Time (min)
post-injection
15 2.24 ± 0.69 19.26 ± 4.98 1.77 ± 0.27 3.94 ± 0.87 0
55 1.98 ± 0.43 5.43 ± 1.42 0.79 ± 0.16 3.03 ± 0.46 0
95 1.36 ± 0.30 2.73 ± 0.54 0.43 ± 0.07 2.21 ± 0.43 0
110 1.18 ± 0.27 2.21 ± 0.39 0.36 ± 0.05 1.98 ± 0.42 0
155 0.81 ± 0.20 1.35 ± 0.22 0.22 ± 0.03 1.30 ± 0.48 0
170 0.72 ± 0.17 1.18 ± 0.17 0.19 ± 0.02 1.17 ± 0.46 0
215 0.44 ± 0.21 0.72 ± 0.29 0.11 ± 0.05 0.79 ± 0.36 0
230 0.39 ± 0.19 0.64 ± 0.25 0.10 ± 0.04 0.70 ± 0.34 0
Residence
time (h)
0.051 ± 0.013 0.153 ± 0.045 0.034 ± 0.011 0.069 ± 0.025 0
an = 8, mean ± SD; non-decay-corrected; bResidence time for trabecular bone; cResid
to 7 were 0.0418 ± 0.0247, 0.0059 ± 0.0037, and 0.0007 ± 0.0002, respectively.assumed to have the same percentage of total body weight
as that for human. The residence time of [18 F]AFM in
the rest of the body was obtained by subtracting the
total organ residence time from the reciprocal of the 18 F
decay constant.rmosan rock monkeysa
pleen Kidneys Bone Red marrow Bladder
.17 ± 0.05 2.09 ± 0.53 7.53 ± 2.71 3.40 ± 0.51 0.07 ± 0.04
.07 ± 0.02 1.26 ± 0.46 11.17 ± 4.35 7.48 ± 1.46 0.62 ± 0.92
.04 ± 0.02 0.74 ± 0.33 9.08 ± 4.36 8.03 ± 2.13 0.78 ± 1.04
.03 ± 0.01 0.63 ± 0.30 8.70 ± 3.97 7.89 ± 2.20 0.82 ± 1.13
.02 ± 0.01 0.41 ± 0.22 7.21 ± 3.23 6.69 ± 2.15 0.67 ± 1.05
.02 ± 0.01 0.35 ± 0.20 6.34 ± 3.12 6.34 ± 2.13 0.66 ± 1.10
.01 ± 0.01 0.20 ± 0.15 4.47 ± 2.44 5.16 ± 1.49 0.47 ± 0.68
.01 ± 0.01 0.17 ± 0.13 4.09 ± 2.42 4.51 ± 1.19 0.42 ± 0.61
.035 ± 0.002 0.019 ± 0.002
0.069 ± 0.031b
0.325 ± 0.080 0.018 ± 0.024d
0.277 ± 0.125c
ence time for cortical bone; dResidence time for subjects 1 to 3, 4 to 5, and 6
Table 3 Radiation dosimetry estimates for [18 F]AFM
using the means of four male and four female monkeys
Male Female Total
Target organ
Adrenalsa 14.0 ± 0.1 16.8 ± 0.4 15.1 ± 1.4
Braina 12.8 ± 2.2 12.4 ± 1.2 12.7 ± 1.8
Breastsa 9.0 ± 0.5 10.5 ± 0.5 9.5 ± 0.9
Gallbladdera 12.6 ± 0.3 13.9 ± 0.8 13.1 ± 0.8
LLI walla 12.4 ± 0.8 15.2 ± 0.8 13.5 ± 1.6
Small intestinea 12.4 ± 0.6 14.0 ± 0.8 13.0 ± 1.0
Stomacha 11.3 ± 0.6 13.7 ± 0.8 12.2 ± 1.4
ULI walla 11.9 ± 0.6 14.5 ± 0.8 12.9 ± 1.4
Heart walla 21.0 ± 1.6 19.3 ± 1.0 20.3 ± 1.6
Kidneysa 18.9 ± 1.3 21.8 ± 0.8 20.0 ± 1.9
Livera 15.7 ± 2.7 14.7 ± 1.8 15.3 ± 2.3
Lungsa 36.6 ± 6.3 32.6 ± 4.6 35.1 ± 5.8
Musclea 10.0 ± 0.4 12.4 ± 0.5 10.9 ± 1.3
Ovariesa 12.8 ± 0.8 15.2 ± 0.8 13.7 ± 1.4
Pancreasea 13.1 ± 0.3 15.4 ± 0.7 14.0 ± 1.2
Red marrowa 35.8 ± 4.8 34.7 ± 6.5 35.4 ± 5.1
Osteogenic cellsa 32.8 ± 4.8 49.5 ± 5.7 39.1 ± 9.8
Skina 7.6 ± 0.3 9.5 ± 0.4 8.3 ± 1.0
Spleena 11.0 ± 1.9 12.0 ± 0.6 11.4 ± 1.6
Testesa 9.0 ± 0.8 - 9.0 ± 0.8
Thymusa 11.5 ± 0.5 13.5 ± 0.6 12.3 ± 1.1
Thyroida 10.3 ± 0.5 12.1 ± 0.5 11.0 ± 1.0
Urinary bladdera 23.1 ± 12.9 11.1 ± 0.7 18.6 ± 11.6
Uterusa 12.6 ± 1.3 14.3 ± 0.8 13.3 ± 1.4
Total bodya 12.2 ± 0.1 15.3 ± 0.0 13.4 ± 1.6
Effective dose equivalent (EDE)b 20.2 ± 0.5 20.6 ± 0.5 20.3 ± 0.5
Effective dose (ED)b 18.0 ± 0.5 18.3 ± 0.4 18.2 ± 0.5
Means of four male and four female monkeys (n = 8, mean ± SD)
extrapolated to 70 kg adult male and female humans. aIn μGy/MBq;
bIn μSv/MBq.
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residence times in all source organs for each monkey by
entering the information into the Java-based OLINDA
1.0/EXM computer program [46] using the model for a
70-kg adult male and female phantom.
Results
Toxicity studies of AFM in rats
The toxicity of AFM was studied in rats using single
dosing and multiple dosing paradigms. The following pa-
rameters were evaluated: mortality/morbidity, clinical
observations, body weights, food consumption, clinical
pathology (hematology and serum chemistry), organ
weights, gross necropsy observation, and microscopic
histopathologic observations. The results showed that
a single iv dosing of AFM tartrate at 987 μg/kg (1,000×
human dosage) or repeated iv dosing at 98.7 μg/kg/day
(100× human dosage) for 5 consecutive days did not
produce overt adverse effects clinically. Thus, AFM
presents minimal toxicity, and its no observable adverse
effect level (NOAEL) is considered to be greater than
987 μg/kg for a single i.v. dose administration and greater
than 98.7 μg/kg/day for a 5-day repeated i.v. dosing
regimen.
Biodistribution of [18 F]AFM in monkeys
Typical whole-body biodistribution of [18 F]AFM in a
Formosan rock monkey was depicted in Figure 1. The
brain, heart, liver, spleen, lungs, kidneys, bladder, and
lumbar vertebrae were visually identified on the images
and treated as source organs of radioactivity for dosimetry
calculation of [18 F]AFM in monkeys. The uptakes of [18 F]
AFM in selected organs are shown in Table 2 and
expressed as percentage injected dose per organ (%ID/
organ, non-decay-corrected). The uptakes of [18 F]AFM in
the lungs, liver, brain, and heart were high in the early
time points and declined slowly for the brain, whereas the
radioactivity declined rapidly in the lungs, liver, and heart.
On the other hand, the uptakes of [18 F]AFM in kidneys,
bladder, red marrow, and bone were low in the beginning
and gradually increased throughout the experiments.
However, there appeared to be significant difference in the
uptake of bladder among individual monkeys. The uptake
of radioactivity in red marrow is difficult to calculate be-
cause it is located within the bones, and 18 F-labelled radi-
oligands might be metabolized through de-fluorination,
leading to bone uptake of [18 F]fluoride ion. Based on the
reported method [38], we estimated that the uptake of
radioactivity in all red marrow of the adult was approxi-
mately 4.7% of the injected activity at 230 min.
Absorbed radiation dose estimates
The residence times of selected organs in monkeys are
also listed in Table 2. Among these organs, red marrow,bone, lungs, liver, and brain had long residence times.
However, the evaluation of residence time in the blad-
der showed larger variations because of the discrepant
biodistribution of [18 F]AFM in the bladder among in-
dividual monkeys. Using the above residence times, the
individual organ doses in humans extrapolated from
the male and female monkeys were calculated with
OLINDA/EXM software, and the results are shown in
Table 3. The osteogenic cells received the highest dose,
followed by red marrow, lungs, heart, kidneys, bladder,
and liver. The effective doses in male and female
humans, according to ICRP 60 [47] and extrapolated
from the data in male and female monkeys, were 20.2
and 20.6 μSv/MBq, respectively.
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[18 F]AFM has been demonstrated to be a promising
SERT imaging agent in rats and baboons [27,34]. In
order to advance it as a potential SERT imaging agent in
humans, it is necessary to estimate its toxicity profile
and the organ radiation dose burden in animal models.
Toxicity studies of AFM were carried out in rats to de-
termine potential toxic effects, identify potential target
organs of toxicity, and determine its NOAEL. Since
some patients may undergo [18 F]AFM PET imaging
more than once during a short period of time (e.g.,
within 1 or 2 weeks), we used both single and multiple
dosing paradigms in the rat toxicity study. The dosages
administered to rats were 100 to 1,000 times more than
the proposed mass dose to be administered to humans.
The results showed that intravenous administration of
AFM tartrate to rats for a single day at 98.7 or 987 μg/kg
(592 or 5,920 μg/m2, 100× or 1,000× the proposed human
dose of 8 μg, respectively) or 5 consecutive days at
98.7 μg/kg/day (592 μg/m2/day, 100× human dose, total
dose of 493.5 μg/kg) did not produce overt adverse effects
clinically nor had any detectable toxicity on any target
organ. Although the maximum tolerated dose (MTD) of
AFM could not be determined from this study, it is be-
lieved to be greater than 987 μg/kg for a single iv doseFigure 2 Typical sagittal view of 4-[18 F]-ADAM whole-body images oadministration and 98.7 μg/kg/day for 5 consecutive days.
Thus, the NOAEL is considered to be greater than
987 μg/kg for a single iv dose administration and greater
than 98.7 μg/kg/day for a 5-day repeated iv dosing regimen
which is similar to those of 4-F-ADAM (1,023.7 μg/kg
for a single iv dose and greater than 102.37 μg/kg/day
for a 5-day repeated iv dosing regimen) [35]. Whole-
body distribution study of [18 F]AFM was carried out in
Formosan rock monkeys. Following [18 F]AFM injection,
the initial uptakes of radioactivity in the brain, lungs,
heart, and liver were high. The radioactivity then
washed out from the brain slowly while it cleared from
the lungs, heart, and liver rapidly (Table 2). The fact that
the uptake of [18 F]AFM in the lungs was high (19.3%
ID/organ at 15 min post-injection) was also observed
for other SERT radioligands, such as [11C](+)McN5652,
[11C]DASB, [123I]ADAM, and 4-[18 F]-ADAM ([35] and
references cited therein). The exact reason(s) for the
high uptake of these radioligands in the lungs was un-
clear. It may be due to the specific binding of the circu-
lating serotonin on pulmonary membranes, nonspecific
binding of amine by the macrophage, and a large blood
volume in the lungs ([35] and references cited therein),
or it may be due to the abundance of SERT expression
in the lungs, with concentration higher than that in thef a male Formosan rock monkey at different time points.
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with time suggesting [18 F]AFM may be eliminated via
the same hepato-billiary and renal pathways as that of
[11C]DASB, [123I]ADAM, and 4-[18 F]-ADAM ([35] and
references cited therein).
SERT are expressed in the brain as well as in various
peripheral organs and tissues such as the adrenals, stom-
ach, gut, spleen, kidneys, lungs, heart, uterus, and bone
marrow [49,50]. Following [18 F]AFM injection, the uptake
of radioactivity in the spine was high (Figure 1). In con-
trast, the uptake of radioactivity in the spine was relatively
low following 4-[18 F]-ADAM injection (Figure 2). If the
uptake of radioactivity in the spine is solely due to the
binding of [18 F]AFM to SERT in the bone marrow within
the spine, then it should also have a similar uptake of
4-[18 F]-ADAM in this region. The fact that the uptake
of [18 F]AFM in the spine was relatively high compared
to that of 4-[18 F]-ADAM (Figure 2) and that its whole
body distribution in monkeys was somewhat similar to
that of [18 F]NaF (Figure 3) suggests that [18 F]AFM
may de-fluorinate in vivo, leading to uptake of the free
[18 F]fluoride in the bone of the spine region. This has
also been observed in another 18 F-labeled SERT imagingFigure 3 Typical sagittal view of [18 F]NaF whole-body images of a magent, [18 F](+)-FMe-McN5652 in rats and humans
[12,51]. It should be pointed out, though, that it may
be tempting to infer that in vivo defluorination occurs
with [18 F]AFM in monkeys, as the 18 F label is located
at the benzylic position of the molecule and presumed
to be labile. However, it is worth noting that while we
were careful to choose regions (radii and ulnae and
lumbar vertebrae) with minimal confounding sources
of radioactivity, the method we used to estimate the
radioactivity in these regions (spine, bone, and red
marrow) is vulnerable to extrapolation error, because
these regions represent a small portion of the total
bone or bone marrow as indicated by Terry et al. [38].
Therefore, at the present, it is reasonable to assume
that uptake in the spine region reflects the combined
contribution of [18 F]AFM binding to SERT in the
spinal cord [52,53] as well as uptake in the marrow and
bone structure. A direct comparison of the whole-body
distribution of [18 F]AFM and [11C]AFM in monkeys
probably will clarify the issue whether the high uptake
of [18 F]AFM in the spine region is solely due to [18 F]
fluoride ion, its binding to SERT or in combination of
both.ale Formosan rock monkey at different time points.
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subjects involved in research studies varied internation-
ally. Radiation risk estimates were recently issued by the
National Institutes of Health (NIH) in the United States,
and the effective dose-estimates are considered to be the
most accurate measure of radiation risks. Based on the
NIH guidelines, the maximum exposure is 50 mSv of
effective dose per year for a research subject [54]. On the
other hand, under the guidelines of the European Com-
mission, the intermediate risk levels in adults will be
equivalent to an effective dose range of 1 to 10 mSv per
annum [55]. To estimate the human dosimetry from the
whole-body PET images data in Formosan rock monkeys,
the organ weight and body mass were used for allometric
scaling after obtaining the residence time of each organ
for each subject. Since the organ weights of the Formosan
rock monkeys are unavailable and the rhesus monkeys
(Macaca mulatta) are genetically similar to the Formosan
rock monkeys [56,57], we used the organ weights of the
rhesus monkey (Macaca mulatta) to calculate the human
dosimetry, similar to what we have done for 4-[18 F]-
ADAM [35]. The results (Table 3) show that the estimated
human dosimetry of [18 F]AFM is 18.21 μSv/MBq which is
comparable to 4-[18 F]-ADAM (19.3 μSv/MBq) and those
of other SERT, DAT, or NET imaging agents ([35] and
references cited therein). The critical organs are the
osteogenic cells, red marrow, and lungs. The lungs are
also reported to be one of the critical organs for other
SERT imaging agents such as [11C]DASB [40,58] and
4-[18 F]-ADAM [35]. However, compared to other widely
used 18 F-radiopharmaceuticals, such as [18 F]FDG (119
μGy/MBq) [59] and [18 F]FDOPA (159 μGy/MBq) [60],
the radiation doses of [18 F]AFM in critical organs are rela-
tively low.
Conclusions
The toxicity studies in rats showed that a single iv dosing
of AFM tartrate at 987 μg/kg (1,000× human dosage) or
repeated iv dosing at 98.7 μg/kg/day (100× human dosage)
for 5 consecutive days did not produce overt adverse ef-
fects clinically. Thus, AFM presents minimal toxicity, and
its NOAEL is considered to be greater than 987 μg/kg for
a single iv dose administration and greater than 98.7 μg/
kg/day for a 5-day repeated iv dosing regimen.
The radiation dosimetry estimates obtained from For-
mosa rock monkeys suggest that the received doses of
most organs range between 8.3 and 39.1 μGy/MBq. The
osteogenic cells, red marrow, and lungs are considered
to be the critical organs with radiation dose burdens of
39.1, 35.4, and 35.1 μGy/MBq, respectively, for male and
female adults, which are all below NIH guidelines. These
results indicate that [18 F]AFM appears to be safe for hu-
man studies from both pharmacologic and radiation ex-
posure perspectives. However, the fact that [18 F]AFMhas relatively low radiochemical yield may hinder its broad
use as a SERT radioligand and a more efficient, high-yield
radiosynthetic method may need to be developed before
its advance to PET imaging applications in humans.
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